Quest Diagnostics Incorporated(DGX)Earnings, Financials & Key Ratios

DGX•NYSE

$189.13

$20.93B mkt cap·21.6× P/E·Price updated May 6, 2026

SectorHealthcare IndustryDiagnostics & Research Sub-IndustryClinical and Specialty Lab Testing

AboutQuest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Show more

Revenue$11.04B+11.8%
EBITDA$2.17B+18.2%
Net Income$992M+13.9%
EPS (Diluted)8.75+13.8%
Gross Margin31.93%-2.8%
EBITDA Margin19.69%+5.7%
Operating Margin14.53%+6.5%
Net Margin8.99%+1.9%
ROE13.99%+6.9%
ROIC8.83%+7.9%
Debt/Equity0.95-7.6%
Interest Coverage6.15-0.8%

Analysis→Technical→

DGX Key Insights

Quest Diagnostics Incorporated (DGX) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓15 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 11.0%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

DGX Price & Volume

Quest Diagnostics Incorporated (DGX) stock price & volume — 10-year historical chart

Loading chart...

DGX Growth Metrics

Quest Diagnostics Incorporated (DGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years3.95%

5 Years3.18%

3 Years3.74%

TTM11.03%

Profit CAGR

10 Years3.42%

5 Years-7.07%

3 Years1.6%

TTM14.16%

EPS CAGR

10 Years6.03%

5 Years-3.62%

3 Years3.12%

TTM14.27%

Return on Capital

10 Years13.22%

5 Years12.92%

3 Years10.83%

Last Year11.48%

DGX Recent Earnings

Quest Diagnostics Incorporated (DGX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 12/12 qtrs (100%)●Beat Revenue 12/12 qtrs (100%)

Q2 2026Latest

Apr 21, 2026

EPS

$2.50

Est $2.37

+5.5%

Revenue

$2.9B

Est $2.8B

+2.3%

Q1 2026

Feb 10, 2026

EPS

$2.42

Est $2.36

+2.5%

Revenue

$2.8B

Est $2.8B

+1.9%

Q4 2025

Oct 21, 2025

EPS

$2.60

Est $2.50

+4.0%

Revenue

$2.8B

Est $2.7B

+2.9%

Q3 2025

Jul 22, 2025

EPS

$2.62

Est $2.57

+1.9%

Revenue

$2.8B

Est $2.7B

+1.3%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 21, 2026	$2.50vs $2.37+5.5%	$2.9Bvs $2.8B+2.3%
Q1 2026	Feb 10, 2026	$2.42vs $2.36+2.5%	$2.8Bvs $2.8B+1.9%
Q4 2025	Oct 21, 2025	$2.60vs $2.50+4.0%	$2.8Bvs $2.7B+2.9%
Q3 2025	Jul 22, 2025	$2.62vs $2.57+1.9%	$2.8Bvs $2.7B+1.3%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
LHLabcorp Holdings Inc.Direct Competitor	21.14B	256.93	24.56	7.25%	6.66%	10.89%	0.83
SLNOSoleno Therapeutics, Inc.Direct Competitor	2.76B	52.94	135.74		10.97%	5.9%	0.01
EXASExact Sciences CorporationDirect Competitor	20.02B	104.91	-95.37	17.69%	-6.4%	-8.66%	1.05
BIOBio-Rad Laboratories, Inc.Product Competitor	6.99B	259.02	9.29	0.65%	6.52%	2.4%	0.21
NEOGNeogen CorporationProduct Competitor	2B	9.18	-1.83	-3.2%	-68.47%	-28.64%	0.44
QDELQuidelOrtho CorporationProduct Competitor	746.18M	10.96	-0.66	-1.89%	-45.57%	-56.31%	1.46
MYRGMYR Group Inc.Product Competitor	7.08B	454.78	60.40	8.79%	3.71%	22.14%	0.16
CERSCerus CorporationProduct Competitor	518.96M	2.59	-31.59	14.35%	-4.41%	-15.18%	1.49

Compare DGX vs Peers

Quest Diagnostics Incorporated (DGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LH

Most directly comparable listed peer for DGX.

Scale Benchmark

vs UNH

Larger-name benchmark to compare DGX against a more recognizable public peer.

Peer Set

Compare Top 5

vs LH, SLNO, EXAS, BIO

DGX Income Statement

Quest Diagnostics Incorporated (DGX) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	7.71B	7.53B	7.73B	9.44B	10.79B	9.88B	9.25B	9.87B	11.04B	11.28B
Revenue Growth %	2.58%	-2.31%	2.59%	22.15%	14.32%	-8.39%	-6.38%	6.7%	11.78%	11.03%
Cost of Goods Sold	4.72B	4.93B	5.04B	5.8B	6.58B	6.45B	6.2B	6.63B	7.51B	7.53B
COGS % of Revenue	61.21%	65.41%	65.2%	61.5%	60.98%	65.26%	67%	67.14%	68.07%	-
Gross Profit	2.99B▲ 0%	2.6B▼ 12.9%	2.69B▲ 3.2%	3.63B▲ 35.1%	4.21B▲ 15.9%	3.43B▼ 18.4%	3.07B▼ 10.6%	3.24B▲ 5.7%	3.52B▲ 8.6%	3.75B▲ 0%
Gross Margin %	38.79%	34.59%	34.8%	38.5%	39.02%	34.74%	33.17%	32.86%	31.93%	33.23%
Gross Profit Growth %	3.14%	-12.88%	3.22%	35.11%	15.85%	-18.44%	-10.6%	5.7%	8.6%	-
Operating Expenses	1.82B	1.5B	1.46B	1.66B	1.83B	2B	1.81B	1.9B	1.92B	2.13B
OpEx % of Revenue	23.67%	19.92%	18.87%	17.61%	16.94%	20.29%	19.53%	19.23%	17.4%	-
Selling, General & Admin	1.75B	1.42B	1.46B	1.55B	1.73B	1.87B	1.61B	1.77B	1.97B	1.98B
SG&A % of Revenue	22.7%	18.91%	18.86%	16.42%	16.01%	18.96%	17.46%	17.93%	17.83%	-
Research & Development	0	0	0	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	16M	-8M	1M	112M	101M	131M	192M	128M	-47M	4M
Operating Income	1.17B▲ 0%	1.1B▼ 5.5%	1.23B▲ 11.8%	1.97B▲ 60.1%	2.38B▲ 20.8%	1.43B▼ 40.0%	1.26B▼ 11.6%	1.35B▲ 6.7%	1.6B▲ 19.1%	1.61B▲ 0%
Operating Margin %	15.11%	14.62%	15.93%	20.89%	22.07%	14.45%	13.64%	13.63%	14.53%	14.31%
Operating Income Growth %	-8.77%	-5.49%	11.81%	60.11%	20.8%	-40.03%	-11.62%	6.66%	19.09%	-
EBITDA	1.44B	1.41B	1.56B	2.33B	2.79B	1.86B	1.7B	1.84B	2.17B	1.95B
EBITDA Margin %	18.61%	18.72%	20.19%	24.71%	25.85%	18.87%	18.39%	18.63%	19.69%	17.25%
EBITDA Growth %	-5.96%	-1.74%	10.64%	49.49%	19.6%	-33.13%	-8.79%	8.11%	18.16%	1.94%
D&A (Non-Cash Add-back)	270M	309M	329M	361M	408M	437M	439M	493M	570M	322M
EBIT	1.18B	1.09B	1.26B	2.05B	2.75B	1.38B	1.29B	1.4B	1.62B	1.66B
Net Interest Income	-151M	-167M	-175M	-163M	-151M	-138M	-152M	-201M	-264M	-260M
Interest Income	2M	2M	5M	3M	1M	10M	11M	25M	0	5M
Interest Expense	153M	169M	180M	166M	152M	148M	163M	226M	264M	265M
Other Income/Expense	-135M	-175M	-98M	-12M	296M	-149M	-106M	-152M	-243M	-214M
Pretax Income	1.03B▲ 0%	926M▼ 10.1%	1.13B▲ 22.4%	1.96B▲ 72.9%	2.68B▲ 36.7%	1.28B▼ 52.2%	1.16B▼ 9.6%	1.19B▲ 3.3%	1.36B▲ 13.9%	1.4B▲ 0%
Pretax Margin %	13.36%	12.3%	14.66%	20.76%	24.81%	12.94%	12.49%	12.09%	12.32%	12.41%
Income Tax	241M	182M	247M	460M	597M	264M	248M	273M	314M	329M
Effective Tax Rate %	23.4%	19.65%	21.8%	23.48%	22.3%	20.64%	21.45%	22.86%	23.09%	23.5%
Net Income	772M▲ 0%	736M▼ 4.7%	858M▲ 16.6%	1.43B▲ 66.8%	2B▲ 39.4%	946M▼ 52.6%	854M▼ 9.7%	871M▲ 2.0%	992M▲ 13.9%	1.02B▲ 0%
Net Margin %	10.01%	9.77%	11.11%	15.16%	18.49%	9.57%	9.23%	8.82%	8.99%	9.08%
Net Income Growth %	19.69%	-4.66%	16.58%	66.78%	39.41%	-52.58%	-9.73%	1.99%	13.89%	14.16%
Net Income (Continuing)	824M	788M	886M	1.5B	2.08B	1.01B	908M	921M	1.05B	1.07B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	114M	128M	122M	132M	118M	114M	111M	118M	116M	300M
EPS (Diluted)	5.50▲ 0%	5.29▼ 3.8%	6.29▲ 18.9%	10.52▲ 67.2%	15.53▲ 47.6%	7.98▼ 48.6%	7.52▼ 5.8%	7.69▲ 2.3%	8.75▲ 13.8%	9.14▲ 0%
EPS Growth %	21.95%	-3.82%	18.9%	67.25%	47.62%	-48.62%	-5.76%	2.26%	13.78%	14.27%
EPS (Basic)	5.63	5.41	6.38	10.68	15.90	8.12	7.59	7.80	8.87	-
Diluted Shares Outstanding	140M	139M	136M	136M	128M	118M	113M	113M	113M	112M
Basic Shares Outstanding	137M	136M	134M	134M	125M	116M	112M	111M	111M	110M
Dividend Payout Ratio	31.99%	36.14%	33.33%	20.75%	15.49%	32.24%	36.77%	38%	35.58%	-

DGX Balance Sheet

Quest Diagnostics Incorporated (DGX) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	1.31B	1.39B	2.49B	3.06B	2.74B	1.9B	2.37B	2.39B	2.38B	2.57B
Cash & Short-Term Investments	137M	135M	1.19B	1.16B	872M	315M	686M	549M	420M	393M
Cash Only	137M	135M	1.19B	1.16B	872M	315M	686M	549M	420M	393M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	924M	1.01B	1.06B	1.52B	1.44B	1.2B	1.21B	1.3B	1.41B	1.59B
Days Sales Outstanding	43.75	49.05	50.22	58.79	48.65	44.13	47.74	48.21	46.57	47.49
Inventory	95M	99M	123M	223M	208M	192M	190M	188M	189M	225M
Days Inventory Outstanding	7.35	7.34	8.91	14.02	11.54	10.87	11.19	10.35	9.18	9.54
Other Current Assets	0	0	0	0	0	196M	286M	351M	361M	361M
Total Non-Current Assets	9.2B	9.61B	10.35B	10.97B	10.87B	10.94B	11.65B	13.76B	13.85B	14.11B
Property, Plant & Equipment	1.15B	1.29B	1.97B	2.23B	2.3B	2.35B	2.42B	2.76B	2.86B	2.88B
Fixed Asset Turnover	6.73x	5.85x	3.92x	4.23x	4.68x	4.20x	3.83x	3.57x	3.86x	3.99x
Goodwill	6.33B	6.56B	6.62B	6.87B	7.09B	7.22B	7.73B	8.86B	8.95B	9.12B
Intangible Assets	1.12B	1.21B	1.12B	1.17B	1.17B	1.09B	1.17B	1.76B	1.64B	1.72B
Long-Term Investments	462M	436M	482M	521M	141M	132M	135M	123M	136M	543M
Other Non-Current Assets	132M	119M	160M	176M	163M	144M	198M	255M	270M	1.09B
Total Assets	10.5B▲ 0%	11B▲ 4.8%	12.84B▲ 16.7%	14.03B▲ 9.2%	13.61B▼ 3.0%	12.84B▼ 5.7%	14.02B▲ 9.2%	16.15B▲ 15.2%	16.23B▲ 0.4%	16.67B▲ 0%
Asset Turnover	0.73x	0.68x	0.60x	0.67x	0.79x	0.77x	0.66x	0.61x	0.68x	0.69x
Asset Growth %	3.99%	4.76%	16.72%	9.21%	-2.96%	-5.69%	9.23%	15.2%	0.45%	21.67%
Total Current Liabilities	1.06B	1.49B	1.99B	1.78B	1.75B	1.55B	1.81B	2.17B	2.28B	2.18B
Accounts Payable	224M	222M	263M	446M	357M	324M	378M	287M	1.6B	1.5B
Days Payables Outstanding	17.33	16.45	19.06	28.05	19.81	18.33	22.26	15.8	77.74	71.09
Short-Term Debt	107M	562M	1.04B	296M	269M	247M	585M	937M	678M	677M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	392M	435M	376M	489M	599M	550M	471M	466M	0	0
Current Ratio	1.24x	0.94x	1.25x	1.72x	1.56x	1.22x	1.31x	1.10x	1.04x	1.04x
Quick Ratio	1.15x	0.87x	1.19x	1.60x	1.44x	1.10x	1.20x	1.02x	0.96x	0.96x
Cash Conversion Cycle	33.77	39.93	40.07	44.77	40.39	36.66	36.67	42.76	-21.99	-14.05
Total Non-Current Liabilities	4.41B	4.17B	5.09B	5.36B	5.3B	5.28B	5.79B	7.09B	6.66B	6.83B
Long-Term Debt	3.75B	3.4B	3.94B	3.99B	4.01B	3.98B	4.41B	5.6B	5.7B	5.73B
Capital Lease Obligations	0	32M	443M	524M	494M	489M	503M	551M	537M	2.19B
Deferred Tax Liabilities	170M	243M	264M	350M	290M	295M	270M	250M	0	0
Other Non-Current Liabilities	493M	502M	447M	497M	502M	517M	606M	688M	420M	2.82B
Total Liabilities	5.47B	5.66B	7.08B	7.13B	7.05B	6.83B	7.6B	9.26B	8.94B	9.01B
Total Debt	3.85B	3.99B	5.42B	4.81B	4.77B	4.71B	5.5B	7.09B	6.92B	6.98B
Net Debt	3.72B	3.86B	4.22B	3.65B	3.9B	4.4B	4.81B	6.54B	6.5B	6.59B
Debt / Equity	0.77x	0.75x	0.94x	0.70x	0.73x	0.78x	0.86x	1.03x	0.95x	0.95x
Debt / EBITDA	2.69x	2.83x	3.47x	2.06x	1.71x	2.53x	3.23x	3.85x	3.18x	3.59x
Net Debt / EBITDA	2.59x	2.73x	2.71x	1.57x	1.40x	2.36x	2.83x	3.56x	2.99x	2.99x
Interest Coverage	7.73x	6.48x	6.98x	12.35x	18.10x	9.34x	7.93x	6.20x	6.15x	6.26x
Total Equity	5.04B▲ 0%	5.34B▲ 6.1%	5.76B▲ 7.8%	6.89B▲ 19.6%	6.56B▼ 4.8%	6.01B▼ 8.5%	6.42B▲ 6.8%	6.9B▲ 7.4%	7.29B▲ 5.7%	7.67B▲ 0%
Equity Growth %	6.29%	6.14%	7.84%	19.57%	-4.77%	-8.46%	6.84%	7.45%	5.66%	30.15%
Book Value per Share	35.96	38.45	42.38	50.67	51.27	50.91	56.80	61.03	64.48	68.45
Total Shareholders' Equity	4.92B	5.22B	5.64B	6.76B	6.44B	5.89B	6.31B	6.78B	7.17B	7.37B
Common Stock	2M	2M	2M	2M	2M	2M	2M	2M	2M	2M
Retained Earnings	7.14B	7.6B	8.17B	9.3B	7.65B	8.29B	8.82B	9.36B	9.99B	10.15B
Treasury Stock	-4.78B	-5B	-5.22B	-5.37B	-3.45B	-4.67B	-4.83B	-4.86B	-5.18B	-5.09B
Accumulated OCI	-48M	-59M	-39M	-21M	-14M	-21M	-14M	-88M	-27M	-43M
Minority Interest	114M	128M	122M	132M	118M	114M	111M	118M	116M	300M

DGX Cash Flow Statement

Quest Diagnostics Incorporated (DGX) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	1.18B	1.2B	1.24B	2B	2.23B	1.72B	1.27B	1.33B	1.89B	1.89B
Operating CF Margin %	15.24%	15.93%	16.09%	21.25%	20.7%	17.38%	13.75%	13.51%	17.09%	-
Operating CF Growth %	9.92%	2.13%	3.58%	61.3%	11.37%	-23.06%	-25.96%	4.87%	41.38%	98.01%
Net Income	824M	788M	906M	1.5B	2.08B	1.01B	908M	921M	1.05B	1.02B
Depreciation & Amortization	270M	309M	329M	361M	408M	437M	439M	493M	570M	432M
Stock-Based Compensation	79M	61M	56M	97M	79M	77M	77M	88M	88M	61M
Deferred Taxes	9M	73M	15M	85M	-57M	1M	-49M	13M	105M	146M
Other Non-Cash Items	309M	18M	-98M	-59M	-364M	69M	42M	20M	27M	203M
Working Capital Changes	-316M	-49M	35M	22M	87M	119M	-145M	-201M	50M	-56M
Change in Receivables	-298M	-65M	-63M	-455M	81M	246M	-15M	-71M	-106M	-185M
Change in Inventory	16M	4M	29M	0	-20M	0	0	0	0	0
Change in Payables	-8M	-19M	73M	452M	35M	-149M	-55M	-67M	129M	170M
Cash from Investing	-805M	-801M	-411M	-772M	21M	-543M	-1.06B	-2.55B	-631M	-668M
Capital Expenditures	-252M	-383M	-400M	-418M	-403M	-404M	-408M	-425M	-527M	-524M
CapEx % of Revenue	3.27%	5.09%	5.18%	4.43%	3.74%	4.09%	4.41%	4.31%	4.78%	-
Acquisitions	-555M	-419M	-58M	-330M	424M	-144M	-611M	-2.16B	-101M	-139M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-252M	-383M	-309M	-415M	-400M	5M	-42M	41M	-3M	-5M
Cash from Financing	-592M	-401M	225M	-1.27B	-2.54B	-1.73B	160M	1.08B	-1.39B	-979M
Debt Issued (Net)	23M	124M	832M	-805M	-2M	-2M	748M	1.54B	-602M	-218M
Equity Issued (Net)	-465M	-322M	-353M	-325M	-2.2B	-1.41B	-275M	-151M	-371M	-354M
Dividends Paid	-247M	-266M	-286M	-297M	-309M	-305M	-314M	-331M	-353M	-357M
Share Repurchases	-465M	-322M	-353M	-325M	-2.2B	-1.41B	-275M	-151M	-450M	-450M
Other Financing	97M	63M	32M	160M	-30M	-17M	1M	23M	-62M	-50M
Net Change in Cash	-222M▲ 0%	-2M▲ 99.1%	1.06B▲ 52950.0%	-34M▼ 103.2%	-286M▼ 741.2%	-557M▼ 94.8%	371M▲ 166.6%	-137M▼ 136.9%	-129M▲ 5.8%	205M▲ 0%
Free Cash Flow	923M▲ 0%	817M▼ 11.5%	843M▲ 3.2%	1.59B▲ 88.3%	1.83B▲ 15.3%	1.31B▼ 28.2%	864M▼ 34.2%	909M▲ 5.2%	1.36B▲ 49.5%	1.33B▲ 0%
FCF Margin %	11.97%	10.85%	10.91%	16.82%	16.96%	13.3%	9.34%	9.21%	12.32%	11.76%
FCF Growth %	18.94%	-11.48%	3.18%	88.26%	15.31%	-28.2%	-34.25%	5.21%	49.5%	25.57%
FCF per Share	6.59	5.88	6.20	11.67	14.30	11.14	7.65	8.04	12.03	12.03
FCF Conversion (FCF/Net Income)	1.52x	1.63x	1.45x	1.40x	1.12x	1.82x	1.49x	1.53x	1.90x	1.29x
Interest Paid	159M	0	0	0	159M	156M	134M	262M	0	157M
Taxes Paid	243M	0	0	0	283M	283M	317M	256M	0	116M

DGX Key Ratios

Quest Diagnostics Incorporated (DGX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	15.8%	14.18%	15.45%	22.62%	29.66%	15.05%	13.75%	13.08%	13.99%	13.8%
Return on Invested Capital (ROIC)	10.36%	9.2%	9.62%	14.4%	17%	10.26%	8.75%	8.19%	8.83%	8.83%
Gross Margin	38.79%	34.59%	34.8%	38.5%	39.02%	34.74%	33.17%	32.86%	31.93%	33.23%
Net Margin	10.01%	9.77%	11.11%	15.16%	18.49%	9.57%	9.23%	8.82%	8.99%	9.08%
Debt / Equity	0.77x	0.75x	0.94x	0.70x	0.73x	0.78x	0.86x	1.03x	0.95x	0.95x
Interest Coverage	7.73x	6.48x	6.98x	12.35x	18.10x	9.34x	7.93x	6.20x	6.15x	6.26x
FCF Conversion	1.52x	1.63x	1.45x	1.40x	1.12x	1.82x	1.49x	1.53x	1.90x	1.29x
Revenue Growth	2.58%	-2.31%	2.59%	22.15%	14.32%	-8.39%	-6.38%	6.7%	11.78%	11.03%

DGX SEC Filings & Documents

Quest Diagnostics Incorporated (DGX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 21, 2026·SEC

Material company update

Mar 12, 2026·SEC

Material company update

Feb 10, 2026·SEC

10-K Annual Reports

FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 20, 2025·SEC

10-Q Quarterly Reports

FY 2026

Apr 22, 2026·SEC

FY 2025

Oct 21, 2025·SEC

FY 2025

Jul 23, 2025·SEC

DGX Frequently Asked Questions

Quest Diagnostics Incorporated (DGX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Quest Diagnostics Incorporated (DGX) reported $11.28B in revenue for fiscal year 2025. This represents a 598% increase from $1.62B in 1996.

Quest Diagnostics Incorporated (DGX) grew revenue by 11.8% over the past year. This is steady growth.

Yes, Quest Diagnostics Incorporated (DGX) is profitable, generating $1.02B in net income for fiscal year 2025 (9.0% net margin).

Dividend & Returns

Yes, Quest Diagnostics Incorporated (DGX) pays a dividend with a yield of 1.65%. This makes it attractive for income-focused investors.

Quest Diagnostics Incorporated (DGX) has a return on equity (ROE) of 14.0%. This is reasonable for most industries.

Quest Diagnostics Incorporated (DGX) generated $1.33B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More DGX

Quest Diagnostics Incorporated (DGX) financial analysis — history, returns, DCA and operating performance tools

Full DGX Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Quest Diagnostics Incorporated(DGX)Earnings, Financials & Key Ratios

DGX Key Insights

✓Strengths

✗Weaknesses

DGX Price & Volume

DGX Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

DGX Recent Earnings

DGX Peer Comparison

Compare DGX vs Peers

vs LH

vs UNH

Compare Top 5

DGX Income Statement

DGX Balance Sheet

DGX Cash Flow Statement

DGX Key Ratios

DGX SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

DGX Frequently Asked Questions

Explore More DGX

Full DGX Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation